Metformin remains the foundational pharmacological intervention for individuals diagnosed with type 2 diabetes mellitus. Operating primarily by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, this agent assists in stabilizing blood glucose levels without the inherent risk of inducing hypoglycemia commonly associated with sulfonylureas. Clinical management involves starting at a low dose to mitigate gastrointestinal side effects such as nausea or abdominal discomfort. Patients must understand that adherence to this medication, combined with structured nutritional adjustments, forms the core of long term glycemic control. Furthermore, monitoring renal function through estimated glomerular filtration rate is a standard clinical safety protocol, ensuring the drug remains safe and effective over years of continuous therapy.